Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome ; volume:22 ; number:1 ; day:14 ; month:1 ; year:2024 ; pages:1-11 ; date:12.2024
Journal of translational medicine ; 22, Heft 1 (14.1.2024), 1-11, 12.2024
- Urheber
-
Zheng, Na
Long, Yihao
Bai, Zixuan
Li, Jianing
Wang, Hongyu
Song, Dan-Dan
Liu, Hong-Lin
Shi, Jian-Hong
Zhao, Shuli
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-023-04779-z
- URN
-
urn:nbn:de:101:1-2024032609350875514032
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zheng, Na
- Long, Yihao
- Bai, Zixuan
- Li, Jianing
- Wang, Hongyu
- Song, Dan-Dan
- Liu, Hong-Lin
- Shi, Jian-Hong
- Zhao, Shuli
- SpringerLink (Online service)
Ähnliche Objekte (12)
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response
Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy
Humanization of the antigen-recognition domain does not impinge on the antigen-binding, cytokine secretion, and antitumor reactivity of humanized nanobody-based CD19-redirected CAR-T cells
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response
Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy
Humanization of the antigen-recognition domain does not impinge on the antigen-binding, cytokine secretion, and antitumor reactivity of humanized nanobody-based CD19-redirected CAR-T cells
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease
CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response
Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Treatment and outcomes of patients with B-ALL relapse after CD19 CAR-T therapy
Humanization of the antigen-recognition domain does not impinge on the antigen-binding, cytokine secretion, and antitumor reactivity of humanized nanobody-based CD19-redirected CAR-T cells
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease